Distinct immune profiles and clinical outcomes in sepsis subphenotypes based on temperature trajectories
- PMID: 39382693
- DOI: 10.1007/s00134-024-07669-0
Distinct immune profiles and clinical outcomes in sepsis subphenotypes based on temperature trajectories
Abstract
Purpose: Sepsis is a heterogeneous syndrome. Identification of sepsis subphenotypes with distinct immune profiles could lead to targeted therapies. This study investigates the immune profiles of patients with sepsis following distinct body temperature patterns (i.e., temperature trajectory subphenotypes).
Methods: Hospitalized patients from four hospitals between 2018 and 2022 with suspicion of infection were included. A previously validated temperature trajectory algorithm was used to classify study patients into temperature trajectory subphenotypes. Microbiological profiles, clinical outcomes, and levels of 31 biomarkers were compared between these subphenotypes.
Results: The 3576 study patients were classified into four temperature trajectory subphenotypes: hyperthermic slow resolvers (N = 563, 16%), hyperthermic fast resolvers (N = 805, 23%), normothermic (N = 1693, 47%), hypothermic (N = 515, 14%). The mortality rate was significantly different between subphenotypes, with the highest rate in hypothermics (14.2%), followed by hyperthermic slow resolvers 6%, normothermic 5.5%, and lowest in hyperthermic fast resolvers 3.6% (p < 0.001). After multiple testing correction for the 31 biomarkers tested, 20 biomarkers remained significantly different between temperature trajectories: angiopoietin-1 (Ang-1), C-reactive protein (CRP), feline McDonough sarcoma-like tyrosine kinase 3 ligand (Flt-3l), granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin (IL)-15, IL-1 receptor antagonist (RA), IL-2, IL-6, IL-7, interferon gamma-induced protein 10 (IP-10), monocyte chemoattractant protein-1 (MCP-1), human macrophage inflammatory protein 3 alpha (MIP-3a), neutrophil gelatinase-associated lipocalin (NGAL), pentraxin-3, thrombomodulin, tissue factor, soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), and vascular cellular adhesion molecule-1 (vCAM-1).The hyperthermic fast and slow resolvers had the highest levels of most pro- and anti-inflammatory cytokines. Hypothermics had suppressed levels of most cytokines but the highest levels of several coagulation markers (Ang-1, thrombomodulin, tissue factor).
Conclusion: Sepsis subphenotypes identified using the universally available measurement of body temperature had distinct immune profiles. Hypothermic patients, who had the highest mortality rate, also had the lowest levels of most pro- and anti-inflammatory cytokines.
Keywords: Artificial intelligence; Fever; Phenotypes; Sepsis; Temperature.
© 2024. Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Conflicts of interest: SVB is supported by NIH/NIGMS K23GM144867. MMC is supported by NIGMS (R01GM123193). MMC has a patent pending (ARCD. P0535US.P2) for risk stratification algorithms for hospitalized patients and has received research support from EarlySense (Tel Aviv, Israel). LS, GLW, AB, SK, DU, LU, and BR are employees of Prenosis.
Similar articles
-
Coronavirus Disease 2019 Temperature Trajectories Correlate With Hyperinflammatory and Hypercoagulable Subphenotypes.Crit Care Med. 2022 Feb 1;50(2):212-223. doi: 10.1097/CCM.0000000000005397. Crit Care Med. 2022. PMID: 35100194 Free PMC article.
-
Temperature Trajectory Subphenotypes Correlate With Immune Responses in Patients With Sepsis.Crit Care Med. 2020 Nov;48(11):1645-1653. doi: 10.1097/CCM.0000000000004610. Crit Care Med. 2020. PMID: 32947475 Free PMC article.
-
Identifying Novel Sepsis Subphenotypes Using Temperature Trajectories.Am J Respir Crit Care Med. 2019 Aug 1;200(3):327-335. doi: 10.1164/rccm.201806-1197OC. Am J Respir Crit Care Med. 2019. PMID: 30789749 Free PMC article.
-
Biomarkers Predicting Tissue Pharmacokinetics of Antimicrobials in Sepsis: A Review.Clin Pharmacokinet. 2022 May;61(5):593-617. doi: 10.1007/s40262-021-01102-1. Epub 2022 Feb 25. Clin Pharmacokinet. 2022. PMID: 35218003 Free PMC article. Review.
-
Genetic and Epigenetic Regulation of the Innate Immune Response to Gout.Immunol Invest. 2023 Apr;52(3):364-397. doi: 10.1080/08820139.2023.2168554. Epub 2023 Feb 6. Immunol Invest. 2023. PMID: 36745138 Review.
Cited by
-
The clinical value of immune cell composition in the diagnosis of pediatric sepsis.Front Pediatr. 2025 Jul 18;13:1599694. doi: 10.3389/fped.2025.1599694. eCollection 2025. Front Pediatr. 2025. PMID: 40755920 Free PMC article.
-
Hydrogen gas therapy: A promising approach for sepsis management post-burn injury by modulating inflammation, oxidative stress, and wound healing.Cytojournal. 2025 Apr 25;22:46. doi: 10.25259/Cytojournal_253_2024. eCollection 2025. Cytojournal. 2025. PMID: 40469704 Free PMC article.
-
On the tightrope between life and graft: immunosuppression in critically ill solid organ transplant recipients.Intensive Care Med. 2025 Aug 19. doi: 10.1007/s00134-025-08061-2. Online ahead of print. Intensive Care Med. 2025. PMID: 40828462 No abstract available.
-
The Role of Immune Semaphorins in Sepsis-A Prospective Cohort Study.Microorganisms. 2024 Dec 12;12(12):2563. doi: 10.3390/microorganisms12122563. Microorganisms. 2024. PMID: 39770766 Free PMC article.
-
A program to improve sepsis management in the Emergency Department: a multicenter prospective study in France.Intern Emerg Med. 2025 Jan 31. doi: 10.1007/s11739-025-03877-8. Online ahead of print. Intern Emerg Med. 2025. PMID: 39888482
References
-
- Singer M, Deutschman CS, Seymour CW et al (2016) The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315(8):801–810. https://doi.org/10.1001/jama.2016.0287 - DOI - PubMed - PMC
-
- Rhee C, Dantes R, Epstein L et al (2017) Incidence and trends of sepsis in US Hospitals Using Clinical vs Claims Data, 2009–2014. JAMA 318(13):1241–1249. https://doi.org/10.1001/jama.2017.13836 - DOI - PubMed - PMC
-
- Freeman BD, Natanson C (2000) Anti-inflammatory therapies in sepsis and septic shock. Expert Opin Investig Drugs 9(7):1651–1663. https://doi.org/10.1517/13543784.9.7.1651 - DOI - PubMed
-
- Lowry SF (1993) Anticytokine therapies in sepsis. New Horizons (Baltimore, Md) 1(1):120–126 - PubMed
-
- Gogos CA, Drosou E, Bassaris HP, Skoutelis A (2000) Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 181(1):176–180. https://doi.org/10.1086/315214 - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous